Brilacidin granted Fast Track designation in the US for the Treatment of COVID-19

Brilacidin is a first-in-class Host Defense Protein mimetic with antiviral, anti-inflammatory and antibacterial properties. It has demonstrated antiviral activity against Covid-19 in laboratory experiments, and a Phase II trial is expected to commence later in January.

Source:

Biospace Inc.